Advances in Non-Hormonal Management of Vasomotor Symptoms (Fezolinetant & beyond)
Basic Overview
Clinical Update Session
Comprehensive review of newly approved NK3 antagonists and other non-hormonal approaches to managing vasomotor symptoms.
Session Details
Key Topics
- Fezolinetant: mechanism and efficacy
- NK3 antagonists in clinical practice
- Patient selection criteria
- Monitoring protocols
- Alternative treatment options
Key Points
NK3 Antagonists
Newly approved NK3 antagonists change the treatment landscape.
Clinical Evidence
Latest research and clinical trial data.
Patient Selection
Identifying suitable candidates for non-hormonal therapy.
Treatment Landscape
Comprehensive overview of available and emerging options.
Speakers